Actively Recruiting
Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean
Led by University Hospital Center of Martinique · Updated on 2025-02-21
590
Participants Needed
1
Research Sites
243 weeks
Total Duration
On this page
Sponsors
U
University Hospital Center of Martinique
Lead Sponsor
E
Ecole des Hautes Etudes en Santé Publique
Collaborating Sponsor
AI-Summary
What this Trial Is About
Dengue fever, an arbovirus transmitted by the Aedes mosquito, is a public health problem in all tropical and subtropical regions of the world. There is currently no antiviral treatment and vector control has shown its limits. The 2018 European marketing authorization of the tetravalent chimeric yellow fever / dengue vaccine (Dengvaxia®) is a major step forward in the fight against the disease. Dengvaxia® is indicated for the prevention of dengue due to serotypes DENV 1-4 in subjects aged 9 to 45 years with a history of infection with the dengue virus and living in endemic areas (seroprevalence of at least 70% in the target population). Dengue seroprevalence data in the French Caribbean territories of Martinique and Guadeloupe dates back to 2011 and concerns only adult blood donors aged 18 to 70 years. To date, no data exists for individuals aged 9 to 17 years in the region. In order to implement an optimal vaccine introduction strategy for these territories, the main aim of the DengueSEA study is to estimate the seroprevalence of the Dengue viruses (DENV 1-4) in 9-17 year olds giving a blood sample as part of care in hospital departments of the French Caribbean islands of Martinique and Guadeloupe.
CONDITIONS
Official Title
Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Child aged 9 to 17 years receiving care at participating hospital departments in Martinique or Guadeloupe
- Need for a blood sample or peripheral venous line as part of the child's care
- Residence in Martinique or Guadeloupe for at least one year
- Study information given to the child and parent or legal guardian
- Parent or legal guardian provides non-objection to the child's participation
You will not qualify if you...
- Child has fever or suspected acute infection
- Child has an immune deficiency or other immune system disorder
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Martinique University Hospital Center
Fort-de-France, Martinique
Actively Recruiting
Research Team
V
Véronique PELONDE-ERIMEE
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here